Quizartinib May Represent an Additional Therapeutic Option for FLT3-ITD+ AML
Mark Levis, MD, PhD, discusses potential changes to the FLT3-ITD-mutated acute myeloid leukemia treatment landscape that may occur if the FDA approves quizartinib, key efficacy and safety data with the agent, and how quizartinib compares with midostaurin.
United States Mark Levis Hematologic Malignancies Bone Marrow Transplant Program Flt3 Itd Mutated Acute Myeloid Leukemia Treatment Landscape Fda Approves Quizartinib
Source: onclive.com